Posted by Michael Wonder on 25 Mar 2021
Akebia Therapeutics announces approval for additional indication of Riona (ferric citrate hydrate) for the treatment of iron deficiency anaemia in adult patients in Japan
24 March 2021 - Akebia Therapeutics today announced that its collaboration partner, Japan Tobacco received approval from the Pharmaceuticals and Medical Devices Agency for an additional indication for Riona 250 mg tablets (ferric citrate hydrate) to treat adult patients with iron deficiency anaemia in Japan.
Ferric citrate is also approved and marketed in the United States by Akebia as Auryxia (ferric citrate) for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis and for the treatment of iron deficiency anaemia in adult patients with chronic kidney disease not on dialysis.
